Physician profile
Louis Lima
NPI 1053302281
$7,225.72
in general payments reported to CMS, 2019-2025
23 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,357 · 2020: $2,083 · 2021: $627 · 2022: $630 · 2023: $484 · 2024: $665 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $3,934.67 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $460.64 | 2019-2025 | Cequa |
| Abbvie INC. | $405.31 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $277.40 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $267.80 | 2022 | |
| Allergan, INC. | $229.13 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $179.88 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $175.03 | 2021-2023 | Flarex |
| Tarsus Pharmaceuticals, INC. | $152.61 | 2024-2025 | Xdemvy |
| Lkc Technologies, INC. | $149.45 | 2024 | |
| Aerie Pharmaceuticals, INC. | $134.11 | 2020-2021 | |
| Sight Sciences, INC. | $128.78 | 2021 | |
| Rayner Intraocular Lenses Limited | $124.99 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $109.06 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.78 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $85.71 | 2020 | |
| Oyster Point Pharma, INC. | $84.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $62.42 | 2020 | |
| Dompe US, INC. | $57.54 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $38.15 | 2021-2025 | Precision7 |
| Astellas Pharma US INC | $25.51 | 2025 | Izervay |
| Harrow Eye, LLC | $21.50 | 2024 | Vevye |
| Biotissue Holdings INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.